A Four-part, Phase 1, Double-blind Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) with Single and Multiple Ascending Oral Doses of OD-07656 in Healthy, Adult Male and Female Participants
Latest Information Update: 26 Feb 2025
At a glance
- Drugs OD 07656 (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Spondylarthritis; Ulcerative colitis
- Focus Adverse reactions; First in man
- Sponsors Odyssey Therapeutics
Most Recent Events
- 11 Feb 2025 Status changed from recruiting to completed.
- 29 Feb 2024 Planned primary completion date changed from 1 Apr 2025 to 1 May 2025.
- 29 Feb 2024 Status changed from not yet recruiting to recruiting.